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Jeroen	Tas:	‘If	we	don’t	look	at	the	big	picture,	we	can
tweak	ourselves	to	oblivion’
When	he	bought	large	orders	of	light	bulbs	for	the	Winter	Palace,	the	Russian	Tsar	became	a	high-profile	customer
of	Philips,	the	Dutch	multinational	corporation	founded	in	1891	to	produce	just	that:	light	bulbs.	But	the	company
never	limited	itself	to	one	line	of	products.	In	the	20th	century,	Philips	became	a	household	name,	with	its	brand
name	stamped	on	a	long	line	of	consumer	electronics.	One	of	its	less	known	areas	was	healthcare:	as	early	as
1918,	Philips	created	a	medical	X-ray	tube,	and	in	1949,	the	Synchrocyclotron,	a	type	of	particle	accelerator	to
study	malignant	tumours.	In	2005	it	became	clear	that	the	multinational	was	pivoting	to	healthcare,	when	it
accelerated	the	process	of	divesting	many	of	its	units	that	“defined	the	company	in	the	eyes	of	the	consumer”,	as
explained	by	Jeroen	Tas,	chief	innovation	and	strategy	officer	and	member	of	the	executive	committee	of	Philips.
This	is	the	type	of	company	transformation	that	attracts	attention	from	academics	and	business	professionals
globally.	Why	take	such	a	big	step?	“If	we	don’t	look	at	the	big	picture,	we	can	tweak	ourselves	to	oblivion”,	Jeroen
told	LSE	Business	Review	managing	editor	Helena	Vieira	on	7	November,	during	the	Web	Summit	conference	in
Lisbon.
How	was	the	decision-making	process	in	this	transformation?	How	difficult	was	it	and	how	did	you	come
up	with	this	decision?
It	was	profound	and	difficult.	The	whole	history	of	Philips	is	technology-driven.	Based	on	that	technology,	you	find
the	application	area.	So,	you	basically	proliferate	your	products,	you	proliferate	the	space	that	you	play	in.	Then	we
said,	okay,	probably	that’s	not	the	right	way	to	go.	We	should	probably	home	in	on	a	specific	domain,	and	then	start
applying	the	right	technology	to	outcomes	in	that	domain.	Basically	you	go	from	technology,	product,	feature,
function,	to	‘how	can	we	be	more	relevant	in	the	space	that	we	elect?’	In	our	case	that	space	was	health
technology.	Should	we	divest	our	generic	consumer	electronics,	televisions,	lighting?	And	also,	these	were	areas
where	we	felt	there’s	very	little	synergy	with	what	we	do	in	the	rest	of	the	organisation.	Philips	was	founded	127
years	ago	as	a	lighting	company.	It’s	pretty	profound	when	we	say	we’re	going	to	IPO	(list	on	the	stock	market)	our
lighting	business	and	get	out	of	it.	It’s	even	worse	when	it	comes	to	television	sets,	because	most	people	associate
the	company	with	TV.	If	you’re	older,	you	think	of	radio.	But	the	point	is	that	we	decided	to	divest	the	stuff	that
defined	the	company	in	the	eyes	of	the	consumer.	And	then,	instead	of	being	a	products	company,	we	said	we
were	going	to	be	a	solutions	company.	And	yes,	we	still	do	products,	but	these	products	will	just	be	building	blocks
for	a	solution.
“We	are	now	using	diagnostic	capabilities	that	we	didn’t	use	earlier
because	it	was	just	too	expensive	and	took	too	much	time.”
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What	is	a	solutions	company?	
When	we	decided	to	focus	on	outcomes	in	certain	domains,	we	pretty	soon	concluded	that	we	can’t	be	a	hardware
company,	or	software	company	or	consultancy.	To	have	real	impact	in	healthcare,	you	need	to	have	depth,	to
understand	the	clinical	context.	That	forces	you	to	go	beyond	just	a	heart.	You	can	look	at	an	MRI	machine	as	a	big
magnet	with	technology	around	it	to	process	the	signals	coming	from	the	machine	and	turn	it	into	an	image.	It’s	a
really	important	diagnostic	capability.	We	want	to	optimise	how	we	use	that	diagnosis	to	be	much	more	precise	in
disease	detection.	In	order	to	do	that,	we’re	going	to	look	at	how	we	can	better	interpret	the	images,	how	we	can
make	the	experience	better	for	the	patient,	how	we	can	make	it	easier	to	select	the	right	configurations	and
protocols.	We	can	start	applying	other	people’s	technologies	to	this.	For	instance,	we	applied	AI	to	develop	images.
Now	we	can	reduce	the	scan	time	for	images	by	almost	50	per	cent,	which	is	a	big	deal.	If	it	goes	down	to	15
minutes,	from	30	minutes,	that’s	big.	We	are	now	using	diagnostic	capabilities	that	we	didn’t	use	earlier	because	it
was	just	too	expensive	and	took	too	much	time.	You	start	looking	at	things	from	a	different	perspective.	We’re
seeing	five	million	people	that	now	get	good	sleep	because	they	have	our	sleep	apnoea	devices.	We	need	to	think
that	60,	maybe	65	per	cent	of	the	adult	population	has	sleep	disorders.	We	have	analysed	billions	of	hours	of	sleep
and	helped	guide	people	towards	better	sleep.	Looking	at	our	experience,	how	can	we	use	our	insights,	whether
they’re	behavioural	or	clinical?	How	can	we	use	our	deep	insights	to	detect	the	disease	even	before	the	patient
suspects	it?	Sleep	apnoea	is	one	of	the	most	under-diagnosed	diseases.	If	we	can	diagnose	it	early,	we	can	avoid
a	lot	of	downstream	clinical	issues	because	it’s	typically	the	first	in	a	series	of	chronic	diseases	that	are	all
interrelated.	So,	if	we	can	help	consumers,	guide	them	towards	better	sleep,	avoid	full	blown	sleep	apnoea,
everybody	wins,	the	consumer	wins,	the	payer	wins,	we	win.	So,	we	reframed	what	we’re	doing.	We’re	no	longer	a
hardware	company,	a	software	company,	or	even	a	services	company.	We’re	all	of	those	things	together.	And	I
think	that’s	a	huge	change.
“If	we	can	apply	deep	insights	and	algorithms	to	patients	at	home,	with
continuous	monitoring,	this	will	have	a	huge	impact	on	the	health	care
system.”
I	was	thinking	that	must	have	taken	a	burning	platform	to	get	you	guys	to	change.
I	always	say	we	don’t	have	a	burning	platform	problem;	we	have	a	boiling	frog	problem.
What’s	the	difference?
A	burning	platform	is	right	in	your	face,	you	see	it	burning.	The	problem	is	the	boiling	frog	problem.	You	put	a	frog	in
water,	and	you	start	heating	the	water.	It	will	start	boiling	gradually,	the	frog	won’t	notice	it,	won’t	jump	out,	and	will
die.	So,	it’s	a	slow	death	without	noticing	it.	I’m	talking	about	some	of	our	bigger	and	more	successful	businesses
that	we	started	transforming.	We’re	hugely	successful	in	patient	monitoring;	43	per	cent	of	all	monitors	in	the	world
are	Phillips,	but	they’re	all	in	intensive	care	units.	They	monitor	seven	vital	signs	and	they	do	it	very	well.	But	vital
signs	are	really	relevant	if	you	know	the	context	of	the	patient,	their	medical	history,	their	current	state,	if	we	can
compare	them	to	other	patients.	We	can	turn	that	into	becoming	predictive.	If	we	can	take	all	these	deep	insights
and	algorithms	and	apply	them	to	patients	at	home,	with	continuous	monitoring	at	home,	this	will	have	a	huge
impact	on	the	health	care	system.	But	you	have	to	change.	Who	are	you?	The	company	that	builds	the	best	and
highest	quality	patient	monitors	for	intensive	care	units?	Or	the	company	that	really	helps	people	by	giving	them
deep	insights	on	the	state	of	their	health?	When	we	are	predictive,	we	tell	people,	‘if	you	stay	on	this	course,	then
this	is	where	you	end	up,	therefore	we	recommend	these	and	these	interventions	to	you’.	That’s	a	different
perspective	on	how	we	extend	and	grow	our	business.
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These	are	still	highly	successful	companies.	But	we	know	that	if	we	don’t	put	them	in	a	different	context	today,	they
may	become	a	burning	platform	or	maybe,	instead	of	a	burning	platform,	every	quarter	it’s	just	going	to	get	a	bit
harder.		You	don’t	notice	it	unless	you	take	a	broader	perspective,	considering	what	the	competition	is	doing,	what
our	customers	are	doing,	and	what	they	are	looking	for.	Over	time,	have	we	addressed	a	bigger	need?	Or	are	we
still	addressing	this	little	need	somewhere	in	the	corner	where	we	keep	tweaking	it?	I	always	tell	people,	‘we	can
tweak	ourselves	to	oblivion’.	You	can	easily	spend	every	day	making	what	you	have	a	little	bit	better.	And	you
should	probably	do	it,	but	at	the	same	time	you	should	be	constantly	asking,	‘am	I	creating	more	relevancy?	Am	I
driving	towards	substantially	better	outcomes?	Or	am	I	doing	something	on	autopilot?’	I	think	it’s	an	easy	risk.	It’s	a
risk	that	a	lot	of	companies	fall	into,	because	it’s	always	easier	when	you	have	a	successful	product	to	just	go	to
your	customers	or	your	key	opinion	leaders.	And	you	ask	them,	‘what’s	the	next	two	or	three	features	you	would	like
to	see	added	to	the	product?’	Most	customers	are	more	than	happy	to	give	you	feedback.	Better	still,	you	can	glean
it	from	the	way	you	use	IoT	and	your	products	and	find	it	out	yourself.	We	constantly	have	to	do	it.	We	have	to	make
our	products	better,	but	at	the	same	time,	that	is	not	sufficient.	You	have	to	keep	looking	at	the	bigger	price,	the
better	outcomes,	the	larger	impact.
“Healthcare	is	never	stand-alone.	It’s	always	an	ecosystem.	we	can
work	with	pharma,	or	join	forces	with	competitors.”
Who	are	your	customers?	Hospitals	and	clinics?	Consumers-patients	like	me?	Governments	monitoring
their	population’s	health?
Big	retailers	in	the	US	like	CVS,	Walmart	and	Walgreens	are	all	getting	into	health	care.	They’re	turning	their	stores
into	health	hubs.	Payers,	health	insurance	companies	are	increasingly	looking	for	companies	like	us	to	help	them
reimburse	in	a	different	way,	to	get	better	outcomes.	If	we	can	help	insurance	companies	identify	those	patients	that
have	sleep	apnoea	and	don’t	know	it,	or	have	diabetes	and	don’t	know	it,	we	can	immediately	intervene	and	point
them	towards	a	therapy	that	may	put	them	in	a	better	place.	That	means	that	insurers	will	have	lower	downstream
costs	for	that	patient.	We	all	know	that	the	cost	will	become	exponentially	higher	if	you	wait	too	long	to	treat	a
chronic	disease,	and	typically	you	have	co-morbidities.	We	have	to	look	at	where	we	can	have	the	biggest	impact.
Traditionally	it	has	been	with	hospitals	and	consumers,	but	now	I	think	our	landscape	has	expanded	substantially.
We’re	talking	regularly	with	government,	specifically	ministries	of	health.	We’re	working	very	closely	with
pharmaceutical	companies.	For	instance,	I	was	recently	talking	to	a	company	that	just	got	FDA	approval	for	an
Alzheimer	drug	that	doesn’t	cure	the	disease,	but	can	stop	it.	It’s	obvious	that	the	earlier	you	catch	it,	the	less	the
impact.	How	can	we	create	a	set	of	diagnostics	that	allow	for	early	screening,	based	on	the	patient’s	risk	profile,
and	how	can	we	make	that	screening	as	easy	and	cheap	as	possible?	We	start	with	the	problem	and	then	we	look
at	our	tools	—	ultrasound,	MRI,	CT.	With	MR	we	can	start	detecting	Alzheimer’s	using	AI,	we	can	start	looking	at
two	studies	in	a	row	which	check	things	like	brain	atrophy,	or	little	spots	in	the	brain	that	may	indicate	Alzheimer’s.
So,	AI	can	come	in	and	help	you	find	signs,	even	where	the	naked	eye	cannot	see	them.	If	you	know	which	patients
are	at	risk,	you	can	put	them	on	an	MRI	screening	programme.	That	used	to	be	very	expensive,	but	with	other
technologies	now,	we	can	hopefully	do	it	in	10-15	minutes.	The	cost	will	go	down.	We	are	flipping	things	around	and
trying	to	find	where	the	impact	is,	or	with	whom	we	can	create	impact.	Healthcare	is	never	stand-alone.	It’s	always
an	ecosystem.	we	can	work	with	pharma,	or	join	forces	with	competitors.	For	instance,	we’re	really	strong	in	cath
labs	(catheterisation	laboratories)	where	we	use	image-guided	catheters	to	go	into	your	body	and	insert	a	stent,	if
you	have	a	clogged	artery.	The	stents	are	not	ours,	they	may	come	from	Medtronic	or	Boston	Scientific.	But	what	if
we	work	closely	with	these	guys	to	make	that	procedure	better?	And	really	align	ourselves,	so	we	can	simulate	the
standard	search	and	quantify	it	beforehand,	so	that	when	we	do	the	procedure,	it	goes	as	smoothly	as	possible.	It’s
no	longer	about	the	features	of	the	cath	lab.	It’s	really	about	optimising	the	procedures	and	with	whom	we	should
work	to	do	that,	so	we	can	improve	the	outcome	for	the	patient,	lower	procedure	costs	and	offer	better	guidance	to
professionals.	So,	we’re	turning	things	around.
What’s	the	importance	of	5G	for	this	e-healthcare	market?
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I	think	5G	is	going	to	be	hugely	important	both	inside	and	outside	the	hospital.	It	will	allow	us	basically	to	integrate
connectivity	into	any	device	at	low	cost.	But	more	importantly,	it’s	self-provisioning.	So	right	now,	doing	stuff	at
home	takes	quite	a	bit	of	effort	to	have	things	connected,	you	have	to	make	sure	it’s	secure.	If	there	are	changes,
then	you	have	to	synchronise.	So,	it’s	not	a	seamless	experience.	For	people	that	have	a	continuous	glucose
metre,	they	may	have	a	wearable	from	Philips	and	they	may	have	a	camera	that	monitors	it.	If	all	of	this	is	self-
configured	and	self-connected	and	has	extremely	low	cost	for	connection,	you	can	create	compelling	experiences.
You	can	also	use	this	for	emergency	care.	For	instance,	a	stroke	is	a	big	issue.	If	somebody	has	a	stroke,	you	have
to	act	very	fast.	There’s	about	one	half	hour	of	what	is	called	time-to-needle,	which	is	the	time	for	a	doctor	to	locate
the	clot	that	blocks	the	blood	flow	in	the	brain.	If	everything	you	need	is	available	in	the	ambulance	(the	CT	scanner,
the	patient	monitoring	information,	the	ECG)	you	can	prep	and	stream	all	the	medical	information;	you	can	identify
which	hospital	has	the	cath	lab	and	the	staff	on	standby	that	can	perform	the	procedure	because	not	all	hospitals
will	have	the	same	availability.	So,	if	you	can	start	making	these	decisions	in	real	time	and	everything	is
synchronised,	you	can	dramatically	improve	acute	care.	And	the	same	applies	for	cardiac	arrest.	I	wrote	a	blog	post
on	the	importance	of	5G	for	emergency	care.
“…(young	doctors)	will	see	that	with	virtual	care	they	will	probably	be
able	to	treat	twice	as	many	patients	in	a	day,	with	better	outcomes.”
Are	you	planning	to	incorporate	upcoming	technologies	such	as	VR	and	AR?	Are	you	integrating	all	of
these	things	in	what	you	do?
It’s	the	same	story.	I	recommend	that	you	look	at	a	procedure	in	a	cath	lab.	When	you	use	big	screens	you	can
literally	see	the	catheter	going	through	the	body,	with	a	combination	of	X	ray,	ultrasound	and	smart	catheters.	The
doctor	has	to	keep	looking	at	the	screen	all	the	time,	and	to	operate	the	C-arm.	We	started	creating	a	solution	with
Microsoft	HoloLens.	And	with	that,	the	interventional	doctor,	the	surgeon,	always	looks	at	the	patient,	and	he	or	she
can	literally	see	the	catheter	going	through	the	body,	overlaid	with	all	the	vital	signs	of	the	patient.	Interestingly,	he
can	pull	out	the	heart.	[Check	a	Microsoft/Philips	promotional	video	below.]	Because	we	use	a	model	of	the	heart
that	gets	populated	with	the	X	ray,	the	ultrasounds	and	maybe	an	earlier	scan,	and	then	he	can	look	at	it	from
different	perspectives.	He	can	essentially	augment	what	he’s	seeing,	and	he	never	leaves	the	side	of	the	patients.
He	uses	a	voice-activated	C-arm,	so	he	can	say,	‘move	left’,	or	‘rotate	90	degrees’.	So,	he’s	just	talking	to	the	C-
arm.	We’re	putting	that	in	clinical	trials	shortly.	We	didn’t	invent	HoloLens.	Microsoft	did.	But	we	started	looking	at
this	technology	as	a	type	of	gaming	technology	that’s	actually	getting	to	a	level	of	maturity,	and	we	can	use	it	in
real-time	medical	procedures.	It’s	amazing	to	see	how	we	start	applying	consumer	technology	to	professional
healthcare.
So,	if	I	survive	another	20	years,	then	I’m	likely	to	grow	to	a	very	old	age,	because	then	all	diseases	will	be
diagnosed	and	treated	or	prevented	early.
You	will,	I	guarantee	you	that,	depending	on	where	you	live	and	if	you	use	Philips	technology.	That’s	the	point.	We
will	be	applying	these	technologies	in	a	consistent,	integrated	way	in	another	10	years.	I	guarantee	you	that	it’s	not
the	technology	holding	it	up.	It’s	the	incentives	system	that	is	holding	up	the	widespread	adoption.	Let’s	say	you’re
a	cardiologist,	and	you	have	worked	for	the	last	30	years	in	the	same	way,	you	schedule	appointments	with	your
patients,	patients	come	into	your	office,	sit	down	and	you	spend	eight	minutes	with	them	doing	a	diagnosis.	Now
you	can	sit	behind	your	screen	and	guide	procedures	in	real	time	with	a	general	practitioner	who	is	sitting	in	with	a
patient.	You	both	look	at	the	patient’s	ultrasounds	and	jointly	do	a	diagnosis	there	and	then.	That’s	quite	different.
There	need	to	be	new	incentives.	Young	doctors	may	want	to	do	that	because	they’ll	see	that	with	virtual	care	they
will	probably	be	able	to	treat	twice	as	many	patients	in	a	day,	with	better	outcomes.	But	it’s	a	big	change.	If	you’re
still	getting	paid	for	eight-to-ten-minute	office	visits,	then	you’re	not	going	to	change	it.	If	you’re	going	to	pay	for
outcomes,	you	should	be	incentivised	to	find	signs	of	congestive	heart	failure,	Alzheimer’s	or	sleep	apnoea	early
on.	The	earlier	we	find	it	the	better	we	treat	it,	the	lower	cost	we	send	downstream.
“Healthcare	is	the	second	largest	industry	in	the	world,	US$7.6	trillion.
But	there’s	no	health	data	infrastructure.”
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I	was	thinking	that	it	may	actually	lead	to	an	increase	in	inequality	in	healthcare.	It’s	already	a	very	unequal
situation	in	the	world	and	a	poor	person	in	Africa,	not	a	rich	one,	will	have	a	much	smaller	chance	of
growing	to	an	old	age	than	me.
There	are	two	things.	There	are	non-clinical	factors	that	directly	relate	to	health,	like	safe	housing,	steady	income,
social	support,	education,	health	care,	access	to	clean	water,	and	sanitation.	These	are	kind	of	table	stakes,	but	we
can	improve	access	to	care.	For	instance,	in	Africa,	we	work	with	120	community	life	centres	that	became	self-
sustaining,	where	we	give	them	basic	diagnostic	capabilities,	a	little	pharmacy,	a	way	to	do	procedures	that	serve	a
community.	(You	can	see	a	short	video	here).	We’re	now	looking	at	extending	that	with	digital	capabilities,	where
people	can	just	use	a	smartphone	for	quick	symptom	checks.	Smart	Q&A,	where	you	ask	a	couple	of	questions	and
you	very	quickly	analyse	a	symptom	and	give	recommendations	when	you	can	remotely	talk	to	a	doctor,	if
necessary.
In	Indonesia,	where	childbirth	mortality	is	high,	we	did	a	project	for	obstetricians.	Indonesia	has	about	15,000
islands,	most	without	obstetricians.	So,	we	created	a	backpack	where	a	nurse	can	come	to	a	village,	examine	the
pregnant	women	and	stream	that	data	to	a	central	system	that	interprets	it	and	sends	back	a	recommendation	from
an	obstetrician.	With	that	you	can	supervise	hundreds	of	patients	anywhere.	And	that	technology	is	at	scale	now,
it’s	being	used.	Again,	you	need	a	system	that	incentivises	this	kind	of	care.	The	government	or	the	health	system
needs	to	embrace	these	technologies,	because	we’re	never	going	to	educate	the	doctors	and	the	nurses	to	create	a
Western	level	system,	but	we	can	leapfrog	through	technology.	You	know,	if	you	go	to	China,	every	doctor	I	talked
to	asked	me	about	what	we’re	doing	in	AI	and	virtual	care,	because	they	want	to	give	small	towns	the	same	quality
of	care	available	in	Beijing	or	Shanghai.	I	believe	there	is	a	huge	opportunity.	Health	care	systems	should	move
from	consultations,	diagnosis,	treatment	and	medication,	to	proactive	population	health	management	using	large
scale	technology.
I	was	probably	unfair	to	Africa.	It’s	not	the	only	continent	where	there’s	poverty	in	the	world.	Poverty	is
everywhere.	There’s	a	lot	of	poverty	and	inequality	in	the	US	too,	for	instance.
Yes,	and	there’s	also	no	access	to	quality	care	in	big	parts	of	the	US.	In	other	parts	of	the	country,	there’s	too	much
healthcare.	Many	tests	and	procedures	that	are	not	really	necessary.	Healthcare	is	not	equal.	Technology-driven
change	can	have	a	positive	impact,	or	it	can	go	the	other	way.	It	really	depends	how	you	govern	it.
Can	we	talk	about	Big	Brother?	Who	is	going	to	control	patients’	private	health	data?
You	should.	You	should	be	in	control	of	your	data.
How	can	I	do	it?
Well,	that’s	another	thing.	Healthcare	is	the	second	largest	industry	in	the	world,	US$7.6	trillion.	If	you	look	at	how
it’s	spent,	you	see	it’s	on	brick-and-mortar	hospitals,	people	(nurses,	doctors,	paramedics),	drugs,	administrative
systems.	But	there’s	no	health	data	infrastructure.	I	come	from	financial	services;	I	can	literally	be	anywhere,
sometimes	without	even	touching	anything.	I	just	hold	my	phone	and	I	can	withdraw	money	anywhere	in	the	world.
And	I’ve	been	to	places	that	barely	have	electricity,	but	I	still	I	could	walk	up	to	an	ATM	and	get	the	money.
Financial	services	have	invested	heavily	in	secure	infrastructures	for	transactions	anywhere	in	the	world	in	real
time.	For	every	transaction,	it	goes	back	and	asks	for	a	personal	authorisation.	There	is	no	reason	why	we	cannot
do	this	in	healthcare.	We	just	need	to	put	the	incentives	in	place.	One	of	my	first	big	impactful	projects	was	when	I
ran	the	tech	lab	for	Citibank,	and	we	launched	internet	banking.	That	was	in	1995,	24	years	ago.	Everybody	said,
‘you’re	completely	wasting	your	time,	nobody’s	ever	going	to	do	their	banking	on	the	internet”.	We	have	an
infrastructure,	we	have	Swift…	And	I	felt	it	was	not	true,	things	were	going	to	change.	I	feel	exactly	the	same	way
about	health	data	now.	It’s	going	to	be	yours;	the	forward-looking	health	systems	are	going	to	give	you	the	tools	to
manage	it.	And	yeah,	it	may	take	a	little	while,	but	I’m	convinced	it	is	going	to	happen,	and	the	systems	that	do	that
will	allow	for	data	donorship,	when	you	donate	your	anonymised	data	for	research,	if	you	want.	This	is	going	to
spawn	innovation.
I	hope	so.
I	hope	so	too.	And	I’ll	do	everything	I	can	do	to	support	and	enable	that.
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